Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932034 · ClinicalTrials.gov registry record
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
A clinical trial, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- 263
- Enrollment target
NCT01932034: Completed study, sponsored by Children's Hospital Los Angeles.
NCT01932034 is a clinical trial that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 263 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01932034 has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- 263 participants
- Enrollment target
Study Summary
We will compare the percentage of patients having therapeutic vancomycin serum concentrations after current standard dosing, after dosing with our software. We will also include therapeutic outcomes and costs in the analysis.
Interventions
- DEVICE BestDose Computer Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2012-09 |
| Est. Completion | 2016-07-04 |
What the finished NCT01932034 record still lists
NCT01932034 is an observational study that tracks outcomes without assigning an intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BestDose Computer Software is the first listed.
NCT01932034 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01932034 about?
NCT01932034 is a clinical study titled "Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software". We will compare the percentage of patients having therapeutic vancomycin serum concentrations after current standard dosing, after dosing with our software. We will also include therapeutic outcomes and costs in the analysis.
What is the current status of trial NCT01932034?
This trial is currently completed. The enrollment target is 263 participants. The study started on 2012-09. Estimated completion is 2016-07-04.
What interventions are being tested in trial NCT01932034?
The interventions under investigation include: BestDose Computer Software (DEVICE).
Who is sponsoring clinical trial NCT01932034?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia